Imperial College London


Faculty of MedicineDepartment of Metabolism, Digestion and Reproduction

Professor of Hepatology. Head of Department



+44 (0)20 3312 1903m.thursz




Ms Dawn Campbell +44 (0)20 3312 6454




Norfolk PlaceSt Mary's Campus





Mark Thursz is professor of hepatology at Imperial College and consultant in hepatology at St Mary's Hospital, London. His clinical interests are in viral hepatitis, alcoholic liver disease and fatty liver disease. He is currently interested in developing programmes for treatment of chronic hepatitis B infection in resource poor settings to reduce the risk of hepatocellular carcinoma.

Professor Thursz' research interests are focussed on the natural history of viral hepatitis and fatty liver disease and the factors which determine chronic infection and progressive liver disease. He has a special interest in the genetic determinants of disease outcomes using genetic association and genome wide scanning to identify causative variants.

Professor Thursz is chief investigator on two multi-centre trials: The warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C) trial and the steroids or pentoxifylline for alcoholic hepatitis (STOPAH) trial.

Professor Thursz is a former secretary of the British Association for Study of the Liver (BASL) and is currently vice-secretary of the European Association for Study of the Liver. In this role he has special responsibility for EU policy and advocacy in Brussels.




Hateley C, Olona A, Halliday L, et al., 2024, Multi-tissue profiling of oxylipins reveal a conserved up-regulation of epoxide:diol ratio that associates with white adipose tissue inflammation and liver steatosis in obesity, Ebiomedicine, Vol:103, ISSN:2352-3964

Thursz M, Mathurin P, 2024, Targeting IL-1 in severe alcohol-related hepatitis: How many frogs will we need to kiss to find an effective therapy?, J Hepatol, Vol:80, Pages:678-680

Gudd C, Mitchell E, Atkinson S, et al., 2024, Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis, Journal for Immunotherapy of Cancer, Vol:12, ISSN:2051-1426

Forlano R, Martinez-Gili L, Takis P, et al., 2024, Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus, Gut Microbes, Vol:16, ISSN:1949-0976

Forlano R, Stanic T, Jayawardana S, et al., 2024, A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies, Liver International, Vol:44, ISSN:1478-3223, Pages:61-71

More Publications